Navigation Links
Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease
Date:5/20/2008

up study, patients completing both initial studies are to be given Cimzia(R) every four weeks for up to seven years. In the second follow-up study, patients who relapsed in either initial study (defined as an increase in CDAI of >70 or absolute CDAI of >350) were re-introduced to Cimzia(R) every four weeks to be continued for up to seven years, with a single additional dose at week 2.

About Crohn's Disease

Crohn's disease is a chronic, progressive, destructive disorder that causes inflammation of the gastrointestinal (GI) tract, most commonly at the end of the small intestine (the ileum) and beginning of the large intestine (the colon). If not effectively treated, it results in the need for surgery. Crohn's disease has been estimated to affect as many as half a million Americans. People with Crohn's can experience an ongoing cycle of flare-up and remission throughout their lives. Together with ulcerative colitis, Crohn's disease is an inflammatory bowel disease (IBD).

About Cimzia(R) (certolizumab pegol)

Cimzia(R) is the first and only PEGylated anti-TNFa (Tumor Necrosis Factor alpha). Cimzia(R) has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation. This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases. UCB is developing Cimzia(R) in Crohn's disease, rheumatoid arthritis and other autoimmune disease indications. Cimzia(R) is a registered trademark of UCB Inc. For full prescribing information, please visit http://www.Cimzia.com.

IMPORTANT SAFETY INFORMATION

Tuberculosis (frequently disseminated or extrapulmonary at clinical presentation), invasive fungal infections, and other opportunistic infections, have bee
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
2. Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
3. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
4. New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
5. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
6. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
7. Gene Therapy Provides Vision to People who Were Nearly Blind
8. Arpida Provides Further Comments on the Pivotal Phase III Trials
9. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
10. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
11. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... Corporation (Nasdaq: LMNX ) today announced that it ... on Monday, February 3, 2014. A press release announcing the ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management ... and financial results for the fourth quarter and twelve months ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis , ... laser tattoo removal experience with the advanced Astanza Duality laser and ... quality cosmetic services with cutting edge medical technology and offering expert ... has seen a dramatic increase in the presence of ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... , NEW ... market research report is available in its catalogue: , ... , http://www.reportlinker.com/p0164335/Cardiac-Pacemakers---A-World-Market-Analysis.html , Pacemaker devices ... devices market. The worldwide cardiac pacemakers market is characterized ...
... , , PALO ALTO, Calif., Dec. ... November 25, 2009, Varian, Inc. filed with the U.S. Securities and ... year ended October 2, 2009. This Annual Report may be ... "Investors" and "SEC Filings," and then on "10-K" in the table ...
Cached Medicine Technology:Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 2Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 3Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 4Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 5Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 6Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 7Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 8Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 9Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 10
(Date:4/17/2014)... Population Council scientists and their partners have found that ... prevent the transmission of multiple sexually transmitted infections (STIs) ... herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). ... the gel is effective against multiple strains of HIV, ... against all three viruses of at least eight hours ...
(Date:4/17/2014)... 2014 Meaningful long-term survival is possible for ... abdomen when treated with cytoreductive surgery with Hyperthermic ... analysis by physicians at Wake Forest Baptist Medical ... reported, single-center experience with cytoreductive surgery and HIPEC, ... analysis of 20 years, worth of patient data ...
(Date:4/17/2014)... world is less than 40 years away from a ... and governments, according to a top scientist at the ... in human history, food production will be limited on ... and energy," said Dr. Fred Davies, senior science advisor ... could become as politically destabilizing by 2050 as energy ...
(Date:4/17/2014)... per cent of Canadians surveyed said they would participate ... specific number of genetic conditions, only 80 per cent ... that would sequence their newborns, genomes.,Most newborns in North ... day or two of life in which a tiny ... tested for about five to 54 conditions, depending on ...
(Date:4/17/2014)... Queen,s University Belfast,s Vice-Chancellor, Professor Patrick Johnston, whose work ... elected as a Fellow of the European Academy of ... is an independent advisory body of highly distinguished oncologists ... and suffering caused by cancer in Europe. , Professor ... Northern Ireland move from the bottom of the UK ...
Breaking Medicine News(10 mins):Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3
... for Special Surgery have identified a group of patients who ... psoas, a condition that usually develops because a teenager or ... psoas tendon. The study will be presented at the annual ... held July 7-11 in San Diego. "The conclusion from ...
... to Herceptin, the main treatment for HER2-positive metastatic breast ... resistant to previous Herceptin-based therapies, according to a study ... Anderson Cancer Center and published in the Journal of ... a combination of the targeted therapies, which play different ...
... HealthDay Reporter , FRIDAY, July 8 (HealthDay News) ... and off the links, but they also are a growing ... Researchers identified 68 people treated for golf cart-related injuries from ... Georgia Health Sciences University in Augusta, not far from the ...
... 8, 2011, Cleveland: Cleveland Clinic researchers have identified a cellular ... in malignant glioma, an aggressive brain tumor. The research ... also found that existing medications block this cancer-promoting pathway ... treatment option for these often fatal brain tumors. Malignant ...
... FRIDAY, July 8 (HealthDay News) -- Meghan Rothschild loved her tan. ... to get a perfect tan was driven by "pure vanity." ... Northampton, Mass. "I hated having a fair complexion. I thought I ... As a result, she said, she hit the tanning booths ...
... the Neglected Tropical Diseases Meeting of the International Society ... Neglected Diseases initiative (DNDi) announced the first research and ... to address unmet needs of patients in Africa and ... of the drug flubendazole to treat a highly neglected ...
Cached Medicine News:Health News:Study identifies patients who should not undergo surgery for a snapping hip tendon 2Health News:Study identifies patients who should not undergo surgery for a snapping hip tendon 3Health News:Targeted agent addition to herceptin has positive effect on metastatic HER-2 breast cancer 2Health News:Targeted agent addition to herceptin has positive effect on metastatic HER-2 breast cancer 3Health News:Golf-Cart Head Injuries on the Upswing, Study Finds 2Health News:Golf-Cart Head Injuries on the Upswing, Study Finds 3Health News:Brain tumor discovery could lead to new treatment 2Health News:From Tanning Beds to Melanoma Surgery 2Health News:From Tanning Beds to Melanoma Surgery 3Health News:DNDi expands activities to neglected patient needs in the field of helminth infections 2Health News:DNDi expands activities to neglected patient needs in the field of helminth infections 3
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
Medicine Products: